Yes, initiate metformin in this patient with type 2 diabetes and normal renal function (eGFR > 45 mL/min/1.73 m²).
Metformin should be started as first-line therapy for this patient, as it is effective at lowering HbA1c, reduces insulin requirements, and carries minimal risk of lactic acidosis when eGFR is above 45 mL/min/1.73 m² 1, 2.
Rationale for Metformin Initiation
The 2025 American Diabetes Association guidelines explicitly recommend metformin as first-line therapy for type 2 diabetes when glucose-lowering is the primary goal 1. This recommendation is based on metformin's proven ability to:
- Reduce HbA1c effectively
- Decrease risks of microvascular complications, cardiovascular events, and death
- Maintain weight neutrality (unlike sulfonylureas or insulin)
- Avoid hypoglycemia risk
- Reduce cardiovascular mortality compared to sulfonylureas 1
Safety Profile with Normal Renal Function
With eGFR > 45 mL/min/1.73 m², metformin carries extremely low risk of lactic acidosis. The FDA labeling confirms metformin can be safely initiated when eGFR is ≥45 mL/min/1.73 m² 2. Multiple large observational studies support this safety threshold:
- A Swedish cohort of 51,675 patients showed metformin reduced risks of acidosis/serious infection (HR 0.85) and all-cause mortality (HR 0.87) even in patients with eGFR 45-60 mL/min/1.73 m² 3
- Systematic review data demonstrate the overall incidence of lactic acidosis in metformin users is only 3-10 per 100,000 person-years, indistinguishable from background rates in the general diabetes population 4
The concern about lactic acidosis is primarily relevant when eGFR falls below 30 mL/min/1.73 m², where metformin accumulation becomes problematic 2.
Practical Dosing Strategy
Start with metformin 500 mg orally twice daily with meals 2. This approach minimizes gastrointestinal side effects (bloating, abdominal discomfort, diarrhea), which are the most common adverse effects. Titrate gradually:
- Increase by 500 mg weekly based on glycemic control and tolerability
- Maximum dose: 2550 mg/day in divided doses
- Consider extended-release formulation if GI intolerance persists 1, 5
Monitoring Requirements
- Assess eGFR at least annually in all patients on metformin 2
- Monitor vitamin B12 levels periodically, as metformin increases risk of B12 deficiency and may worsen neuropathy symptoms 1, 5
- Reassess benefit-risk if eGFR later falls below 45 mL/min/1.73 m² 2
Critical Contraindications to Avoid
Even with normal renal function, temporarily discontinue metformin in these situations to prevent lactic acidosis 2:
- Iodinated contrast procedures (hold starting day of procedure through 48 hours post-procedure if eGFR 30-60 mL/min/1.73 m²) 2, 6
- Acute illness with risk of volume depletion or hypoperfusion (sepsis, acute heart failure, shock)
- Surgical procedures requiring restricted food/fluid intake
- Conditions causing hypoxemia 2
Educate the patient on "sick-day rules": stop metformin during acute intercurrent illnesses 7.
Expected Outcomes
Metformin monotherapy typically reduces HbA1c by 1-2%. If HbA1c remains ≥1.5% above individualized goal, dual-combination therapy or more potent agents will be needed 1. The insulin-sparing effect helps reduce insulin requirements while maintaining glycemic control.
Bottom line: Start metformin 500 mg twice daily with meals in this patient with eGFR > 45 mL/min/1.73 m², titrate gradually, monitor renal function annually, and educate on temporary discontinuation during acute illness.